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Abstract
Background: There have been inconsistent findings on the association between current drug use and HIV disease
progression and virologic suppression. Drug use was often measured using self-report of historical use. Objective
measurement of current drug use is preferred.
Methods: In this cross-sectional study, we assessed drug use through Computer-Assisted Self Interviews (CASI) and
point-of-care urine drug screen (UDS) among 225 HIV-infected patients, and evaluated the association between
current drug use and virologic suppression.
Results: About half (54%) of participants had a positive UDS, with a lower self-reported rate by CASI (42%) (Kappa
score = 0.59). By UDS, 36.0% were positive for marijuana, 25.8% for cocaine, 7.6% for opiates, and 2.2% for
methamphetamine or amphetamine. Factors associated with virologic suppression (plasma HIV RNA <50 copies/mL)
were Caucasian race (P = 0.03), higher CD4 count (P < 0.01), current use of antiretroviral therapy (ART) (P < 0.01), and a
negative UDS (P < 0.01). Among 178 current ART users, a positive UDS remained significantly associated with lower
likelihood of virologic suppression (P = 0.04).
Conclusions: UDS had good agreement with CASI in detecting frequently used drugs such as marijuana and cocaine.
UDS at routine clinic visits may provide “real-time” prognostic information to optimize management.
Keywords: Drug use, HIV, Computer-assisted self-interview, Urine drug screen, Antiretroviral therapy, Virologic
suppression
Background
The introduction of antiretroviral therapy (ART) has re-
sulted in a decline in AIDS-defining events and mortality
in HIV-infected populations. Studies suggest, however,
that people who use drugs (PWUD), particularly those
who inject drugs, may not achieve the same benefits from
treatment as persons who do not use drugs [1,2]. Even
when controlled for adherence to ART, outcomes for
PWUD may be poorer compared to non-users [3]. How-
ever, other studies have shown conflicting results with
minimal or no association between drug use and HIV
disease progression [4,5]. These discordant findings may
be due to differences in measuring drug use, such as the
type of drugs used, route of administration, dose and fre-
quency, current or past use, and polydrug use [4,6].
There are numerous ways of measuring drug use in re-
search and clinical care settings. Traditional paper-based
questionnaire surveys, either self-completed or adminis-
tered by an interviewer, are relatively inexpensive and
easy to implement, but are subject to social desirability
bias due to stigma associated with drug using behaviors
[7,8]. Computer Assisted Self Interview (CASI) may re-
duce but not eliminate such bias [9-11]. Both question-
naire and CASI interviews can assess past and current use
of drugs. In contrast, direct drug testing by urine drug
screen (UDS) detects metabolites in urine samples with
good sensitivity and specificity [12,13], and therefore
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provides an objective assessment, but is more costly and
may be impractical for routine use in some settings. As
the window for detecting metabolites in urine typically
ranges from a few hours to two weeks, a positive UDS in-
dicates current or recent drug use [13]. Studies on the re-
lationship between use of illicit drugs and HIV disease
outcomes often use self-reported history of drug use.
There is a scarcity of literature on validation of reported
drug use and on the assessments of current drug use and
its potential association with HIV treatment outcomes
among HIV-infected patients [3,14]. We assessed the
agreement between CASI and UDS results in this group of
HIV-infected participants, and the relationship between
virologic suppression and drug use as assessed by UDS.
Methods
Study setting and target population
The study was conducted during June 2010 and December
2011 at the Vanderbilt Comprehensive Care Clinic
(VCCC), a large outpatient HIV clinic in Nashville,
Tennessee that provides integrated HIV and psychiatric
care, and social work services to over 2,800 patients in ac-
tive care. An estimated 80% of patients at VCCC are from
Middle Tennessee; the remaining are from other parts of
Tennessee or from surrounding states of Kentucky,
Georgia, West Virginia, Alabama and Arkansas. Patients
were recruited by a research nurse during clinic visits at
VCCC, where they read brochures about this drug use-
related study then voluntarily decided to participate in the
study. About one out of three patients approached by the
nurse agreed to participate in the study. Each participant
provided a written informed consent for completing a
CASI interview, providing urine sample for UDS, and giv-
ing permission of use of their clinical data. A $10 gift card
was given to participants who completed the study proce-
dures. The study protocol was approved by the institu-
tional review board of Vanderbilt University. Approval
was granted to incorporate data collected from this study
into the VCCC data and specimen repository for future re-
search use, but study data were kept separate from the
medical record.
Computer-assisted self interview
CASI was conducted to collect data on drug and alcohol
use, depression, and adherence to antiretroviral therapy
(ART). Participants were asked 3-item AUDIT alcohol
consumption questions (AUDIT-C) to query for prob-
lematic drinking [15,16]. Participants were also asked to
indicate whether or not they had used a variety of illicit
substances in the past 7 days, 6 months and lifetime
using a modified version of WHO-ASSIST (Alcohol,
Smoking & Substance Involvement Screening Test) ques-
tionnaire. Substances included cocaine/crack, marijuana,
heroin or other opiates, methamphetamine (crystal meth),
pain medications, benzodiazepines, and inhalants. The 9-
item Patient Health Questionnaire (PHQ-9) Depression
Module was used to screen for depression. The 4-item
AIDS Clinical Trials Group (ACTG) Questionnaire for
Adherence to Antiretroviral Medications was used to as-
sess ART adherence [17].
Urine drug screen
All participants undertook a point-of-care UDS. The
FDA-approved QuickScreen™ Pro 5 Drug Test Card (Craig
Medical Distribution, Inc. Vista, CA) was used [18]. It is a
one-step panel immunoassay for the qualitative detection
of amphetamine, benzoylecgonine (cocaine metabolite),
methamphetamine (including Ecstasy), opiates (morphine/
heroin metabolite) and marijuana in human urine. Am-
phetamine has a half-life of 4–24 hours in the body and
methamphetamine has a half-life of 9–24 hours; cocaine
can generally be detected for 24–48 hours after exposure;
the half-life of opiate drugs may range from 2 to 32 hours,
e.g., 8–12 hours for heroin; marijuana remains detectable
for 3–10 days after smoking. The visual one-step panel
urine test provides a qualitative “yes or no” report in 5 mi-
nutes. According to the package inserts of the testing kit,
the agreement rates of detecting the individual drugs using
the QuickScreen™ Pro 5 Drug Test Card and confirmatory
gas chromatography–mass spectrometry range from 95%
to 98%. A trained research nurse performed UDS and re-
corded the results. While waiting for UDS results, patients
completed CASI.
Clinical data
Data retrieved from the clinical database at VCCC in-
cluded socio-demographics, ART use, and the latest values
of CD4 count and HIV RNA in plasma measured by
standard procedures as part of routine care. The values of
CD4 and viral load that were closest to the survey date
were used in the analysis, most within 3 months of the
survey and few between 3–6 months. Virologic suppres-
sion was defined as plasma HIV RNA <50 copies/mL.
Data analysis
The AUDIT-C is scored on a scale of 0 to 12, and the
scores of ≥4 in men and ≥3 in women were defined as
unhealthy alcohol use [15,19]. Current drug use was de-
fined as a positive result on any of five tested drugs in
UDS. We did not assess relationships with specific drugs
due to limited study sample size. The PHQ-9 is scored
on a scale of 0 to 27, and the scores of ≥10 were defined
as major depression (mediate or severe depression) [20].
ART adherence was defined by whether having missed at
least one dose of ART in past 4 days. Virologic suppres-
sion was defined as HIV-1 RNA < 50 copies/mL.
We calculated the detection rate of drug use by UDS
and the rates of drug use during the past 7 days, the past
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6 months, and lifetime use by CASI self-report. We then
calculated the agreement (Kappa score) of detecting
current drug use by CASI 7-day report and UDS. We
considered self-reported 7-day drug use as current use.
The Kappa scores are interpreted as: < 0 indicating no
agreement, 0–0.20 slight, 0.21–0.40 fair, 0.41–0.60 mod-
erate, 0.61–0.80 substantial, and 0.81–1 almost perfect
agreement [21].
We performed multivariate logistic regression analysis
in the entire study sample to evaluate the relationship
between current use of any drugs as determined by UDS
and virologic suppression while adjusting for covariates.
We also performed subgroup analysis among patients
who had received ART only, because prescription of
ART may be less likely to occur for drug using patients
than for non-users [22]. We selected covariates and fit-
ted regression models based on our cohort analysis in
the same study population [1]. We re-analyzed the data
and did not find interaction between ART and drug use.
Therefore, we use the parsimonious models without
interaction term.
Results
A total of 226 HIV-infected patients participated in the
study; one participant did not provide a urine sample for
UDS and was excluded from the analysis. Of 225 partici-
pants, about 30% were female; the mean age was 43 years
(median 49; range 19–66); 38% were Caucasians, and
59% were African Americans (Table 1).
Nearly 38% of participants reported unhealthy alcohol
use; 25% had moderate or severe depression (Table 1).
Of the 80% of patients who were prescribed ART, 32%
reported missing at least one dose in the past 4 days
(data not shown).
Table 2 presents the prevalence of drug use by UDS and
CASI. About half (53.5%) had a positive UDS for any drug.
Over one third (36.0%) were positive for marijuana, 25.8%
for cocaine, 7.6% of opiates, 2.2% for methamphetamine
or amphetamine. The CASI reported rate of using any
drugs in the past 7 days was 42.0%, which was significantly
lower than that by UDS (less than the lower bound of 95%
confidence interval of UDS rate). CASI also reported
lower rates of marijuana (28.6%) and cocaine (18.9%) use
than corresponding positive UDS rates. Ninety-two per-
cent of participants reported any lifetime drug use.
Though nearly a quarter of participants reported ever
injecting drugs, very few reported injection drug use in
the past seven days (0.4%) or six months (1.8%).
Table 3 presents the agreement statistic Kappa values
for detecting drug use by UDS and CASI reported 7-day
drug use. The Kappa values for marijuana and cocaine
were 0.68 and 0.71, respectively, indicating substantial
agreement; and the Kappa value for any drugs was 0.59,
indicating moderate agreement. For other infrequently
used drugs, the agreement was poor.
Factors associated with virologic suppression were
Caucasian race (versus non-Caucasian; adjusted odds ra-
tio [AOR] 2.5; 95% confidence interval [CI] 1.1-5.7),
CD4 count (per 10 cell/uL increase; AOR 1.003; 95% CI
1.001-1.004), current use of ART (AOR 8.3; 95% CI 3.1-
22.3), and current drug use by UDS (a positive UDS was
associated with a significantly lower odds of virologic
suppression: AOR 0.3; 95% CI 0.1-0.7). There was still a
statistically significant association between current drug
use and lack of virologic suppression among the sub-
group of participants who were currently prescribed
ART (AOR 0.4; 95% CI 0.2-0.9) (Table 4).
Discussion
Our study is one of few studies comparing self-report
and UDS in measuring drug use [14,23-25] and the only
study to our knowledge among HIV-infected patients.
We found that CASI and point-of-care UDS had fair
agreement in detecting current use of common drugs
such as marijuana and cocaine among HIV-infected pa-
tients, but had poor agreement for infrequently used








Sex (male) 157 (69.8%) 86 (54.8%) 71 (45.2%) 0.65
Age, year (mean ± SD) 42.7 ± 10.1 44.0 ± 10.0 41.2 ± 10.2 0.04
Race 0.01
White 86 (38.2%) 40 (46.5%) 46 (53.5%)
Black 132 (58.7%) 80 (60.6%) 52 (39.4%)
Other 7 (3.1%) 1 (14.3%) 6 (85.7%)
Unhealthy alcohol use 85 (37.7%) 49 (57.6%) 36 (42.4%) 0.71
Major depression (≥moderate level) 57 (25.3%) 29 (50.9%) 28 (49.1%) 0.67
ART, yes 179 (79.6%) 94 (52.5%) 85 (47.5%) 0.63
Note: UDS: urine drug screen; SD: standard deviation.
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drugs. CASI tends to underreport current drug use com-
pared to UDS. Only about 10% of participants (n = 24)
ever received drug or alcohol treatment in the past
6 months, and the treatment experience had no signifi-
cant impact on the difference of detecting drug use by
UDS and self-report. A study among college students
showed that the overall result in detecting any drug use
was satisfactory, while the sensitivity of self-report on
more stigmatized drugs such as cocaine was lower than
that on less stigmatized drugs such as marijuana (canna-
bis) among college students [14], and these findings are
consistent with another study among men who have sex
with men and the general population [24]. One advan-
tage of CASI is that it can assess drug use for longer pe-
riods of time, such as past 6 months or lifetime.
However, serial UDS at repeated clinic visits may also
allow longer-term assessment and is also less likely to be
subject to reporting bias.
Lifetime and current drug use was very common
among this group of HIV-infected, predominantly ART-
treated participants recruited during clinical visits and
thus engaged in care to some degree. Current drug use
was associated with lower likelihood of virologic sup-
pression among ART-treated participants. Drug use may
lead to suboptimal HIV treatment outcomes through
both biological and behavioral mechanisms. For ex-
ample, PWUD may have poor adherence to ART; illicit
drugs such as amphetamines, cocaine, marijuana, and
opiates may alter immune function and increase suscep-
tibility to infection [4,26]. Rapid point-of-care screening
for drug use at routine clinic visits may provide useful
“real time” prognostic information for HIV treatment ef-
ficacy and optimize management decisions by identifying
persons at greatest risk for treatment failure, guiding de-
cisions regarding targeted adherence counseling, timely
referral to appropriate drug use treatment programs,
and testing for viral resistance. We did not find an asso-
ciation between unhealthy alcohol use and virologic sup-
pression, although there is biological plausibility [27].
Evidences on the relationship between heavy alcohol
consumption and HIV outcomes are inconsistent [27].
Table 2 Prevalence of drug use by point-of-care urine
drug screen (UDS) and Computer-Assisted Self Interview











Any drugs 53.5 (47.0-60.0) 42.0‡ 59.3 92.4
Marijuana 36.0 (29.7-42.3) 28.6‡ 44.1 85.0
Cocaine 25.8 (20.1-31.5) 18.9‡ 29.5 66.8
Opiates 7.6 (4.1-10.1) 7.5 18.5 43.8
Meth/amphetamine 2.2 (0.3-4.1) 1.8 6.2 25.2
Injection N/A 0.4 1.8 23.7
Note: CI: confidence interval; N/A: not applicable.
*95% CI was calculated in order to assess whether or not the CASI point
estimate was likely to be within 95% CI of the UDS estimate.
‡The prevalence of 7-day drug use by CASI is less than the lower bound of
95% CI of the prevalence by UDS.
Table 3 Agreement in detecting drug use by point-of-care urine drug screen (UDS) and Computer-Assisted Self
Interview (CASI)
CASI reported 7-day use UDS Kappa coefficient
(+) (−) total
Any drugs (+) 84 (37.3%) 10 (4.4%) 94 (41.8%) 0.59
(−) 37 (16.4%) 94 (41.8%) 131 (58.2%)
Total 121 (53.8%) 104 (46.2%) 225 (100.0%)
Marijuana (+) 57 (25.3%) 8 (3.6%) 65 (28.9%) 0.68
(−) 24 (10.7%) 136 (60.4%) 160 (71.1%)
Total 81 (36.0%) 144 (64.0%) 225 (100.0%)
Cocaine (+) 39 (17.3%) 3 (1.3%) 42 (18.7%) 0.71
(−) 19 (8.4%) 164 (72.9%) 183 (81.3%)
Total 58 (25.8%) 167 (74.2%) 225 (100.0%)
Opiates (+) 2 (0.9%) 15 (6.7%) 17 (7.6%) 0.05
(−) 15 (6.7%) 193 (85.8%) 208 (92.4%)
Total 17 (7.6%) 208 (92.4%) 225 (100.0%)
Methamphetamine (+) 0 (0.0%) 4 (1.8%) 4 (1.8%) −0.01
(−) 5 (2.2%) 216 (96.0%) 221 (98.2%)
Total 5 (2.2%) 220 (97.8%) 225 (100.0%)
Note: CI: confidence interval; (+): positive screen or reported use; (−): negative screen or reported no use.
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Our study suggests the potential treatment benefits of
integrating routine screening for substance use in HIV
clinics, with and without the use of UDS. The detection
of drug use will alert physicians to consider providing
drug abuse treatment and counseling in order to achieve
optimal HIV treatment outcome. Meanwhile, there are
numerous issues that may arise from implementing rou-
tine point-of-care UDS for all HIV-infected patients. Pa-
tients may have concerns about drug use status being
disclosed to their employers or insurers, and their views
on integrated HIV primary care and drug screening and
treatment should be taken into consideration [28]. Phy-
sicians may provide differential care to drug-using pa-
tients, including deferring ART treatment [29]. The cost
of UDS may not be reimbursed from patients’ insurance
plans. Concerns about routine UDS may increase the
likelihood that some patients would miss medical ap-
pointments. Therefore, instead of universal UDS for all
HIV-infected patients, opt-out UDS could be considered.
Finally, from the perspective of clinic administrators,
implementing routine point-of-care UDS would require
additional personnel and lab space.
Our study has several limitations. The length of time
during which different drugs or their metabolites can be
detected in urine samples depends on many factors, in-
cluding chemical properties (e.g., half-life), metabolism
rates and excretion routes, amount consumed, adminis-
tration route, frequency and chronicity of use, and indi-
vidual variations in patients’ physical health, exercise,
diet, weight, gender, and fluid intake that may affect ex-
cretion rates [30], and it is generally 2–5 days with a
range from 24 hours up to 14 days. The QuickScreen™
Pro 5 Drug Test Card is convenient to use but provides
only a preliminary analytical test result; in comparison,
confirmatory methods such as gas chromatography/mass
spectrometry (GC/MS) are expensive. Therefore, our
UDS findings might underestimate drug use. We did not
assess use of prescription opioid use, which might be
common among HIV-infected patients [31]. This topic
warrants research. The study participants were recruited
as a convenience sample through brochures advertising
a drug use-related study. This recruitment likely led to
an enrichment of the population who currently used
drugs and an overestimation of current drug use, but it
should not affect the validity of assessing test agreement
or the relationship between current drug use and viro-
logic suppression. Adherence to ART, a key covariate in
assessing the relationship between drug use and viral
suppression, was based on self-report, which may result
in overestimation of adherence; pharmacy data and
Medication Event Monitoring System (MEMS) could be
considered as alternative measures [32,33]. Due to the
cross-sectional nature of the study, we could not ascertain
the temporal relationship between drug use and virologic
suppression. Prospective cohort studies with longitudinal
assessment of point-of-care drug use screening and HIV
outcomes are needed.
Conclusions
UDS at routine clinic visits may provide “real-time”
prognostic information to optimize HIV care, but studies
are needed to evaluate its acceptability among patients
and providers.
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Table 4 Multivariate logistic regression analyses of factors associated with HIV suppression (<50 copies/mL) among
225 HIV-infected patients
Variable
Model 1: overall Model 2: ART users
(N = 225) (N = 178)
Adjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Sex (male vs. female) 1.38 0.63-3.02 0.42 1.29 0.53-3.18 0.57
Age, 1 year increase 1.01 0.97-1.05 0.54 1.02 0.97-1.07 0.33
Race (Caucasian vs. non-Caucasian) 2.50 1.10-5.68 0.03 3.29 1.20-9.06 0.02
CD4 count, 10 cells/uL increase 1.003 1.001-1.004 <0.01 1.003 1.001-1.004 <0.01
Current use of ART 8.29 3.08-22.30 <0.01
Missed at least one dose of ART in past 4 days 0.93 0.37-2.35 0.87
Current drug use by UDS 0.33 0.15-0.73 <0.01 0.38 0.15-0.94 0.04
Unhealthy alcohol use 1.12 0.52-2.44 0.77 1.02 0.43-2.44 0.97
Major depression (≥moderate level) 0.72 0.31-1.69 0.44 0.89 0.32-2.43 0.81
OR: odds ratio; CI: confidence interval; UDS: urine drug screen.
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